Halda Therapeutics Announces Appointment of Eyal Attar, MD, as Chief Medical Officer [Yahoo! Finance]
Aprea Therapeutics, Inc. (APRE)
Company Research
Source: Yahoo! Finance
therapies called RIPTAC TM (Regulated Induced Proximity Targeting Chimeras) therapeutics, today announced that Dr. Eyal Attar has joined the company as Chief Medical Officer (CMO). Dr. Attar brings to Halda over 25 years of biotechnology R&D and clinical trial experience in the advancement of novel therapeutics. "Dr. Attar is a seasoned biotechnology industry veteran, and we are thrilled for him join the Halda team at this exciting time," said Christian Schade, President and CEO of Halda Therapeutics. "As Halda advances our novel small molecule RIPTAC modality in clinical studies, the breadth of Eyal's clinical development and R&D strategy experience will be instrumental to achieving our ambitious development goals and future success." "Halda's novel RIPTAC small molecule platform is a new and exciting modality in the treatment of patients with cancer and other serious diseases," said Dr. Attar, Halda's incoming CMO. "I look forward to working with the outstanding team at Halda an
Show less
Read more
Impact Snapshot
Event Time:
APRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APRE alerts
High impacting Aprea Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
APRE
News
- Aprea Therapeutics (NASDAQ:APRE) had its price target lowered by analysts at HC Wainwright from $20.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026GlobeNewswire
- Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswire
- Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update [Yahoo! Finance]Yahoo! Finance
- Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical UpdateGlobeNewswire
APRE
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- APRE's page on the SEC website